ArticlemSphere2019
Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure.
Open access · goldAbstract read
In one paragraph
Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Genome-Wide Analysis of the Malaria ParasiteFrontiers in immunology · 2020Trial
- A subset of Plasmodium falciparum RIFINs is linked to severe malaria risk reduction and engages LILRB1 through a conserved structural motif.EBioMedicine · 2025Article
- Conserved multiepitopes inEmerging microbes & infections · 2025Article
- Article
- Children with hemoglobin C or S trait have low serologic responses to a subset of malaria variant surface antigens.The Journal of infection · 2024Article
- Natural immunity to malaria preferentially targets the endothelial protein C receptor-binding regions of PfEMP1s.mSphere · 2023Article
- STRIDE: a command-line HMM-based identifier and sub-classifier of Plasmodium falciparum RIFIN and STEVOR variant surface antigen families.BMC bioinformatics · 2022Article
- Antibody signatures of asymptomatic Plasmodium falciparum malaria infections measured from dried blood spots.Malaria journal · 2021Article
- Malian adults maintain serologic responses to virulent PfEMP1s amid seasonal patterns of fluctuation.Scientific reports · 2021Article
- Rapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays.Journal of proteome research · 2020Review
- Production of high-complexity frameshift neoantigen peptide microarrays.RSC advances · 2020Article
- Naturally Acquired Humoral Immunity AgainstFrontiers in immunology · 2020Review
- Global Repertoire of Human Antibodies AgainstFrontiers in immunology · 2020Article
- Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL-α tag.Malaria journal · 2019Article
- Article
- Clinical expression and antigenic profiles of a Plasmodium vivax vaccine candidate: merozoite surface protein 7 (PvMSP-7).Malaria journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 3 countries.
Albert E ZhouMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Andrea A BerryMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jason A BaileyThe EMMES Corporation, Rockville, Maryland, USA.
Andrew PikeMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Antoine DaraMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Sonia AgrawalMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Emily M StuckeMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Amed OuattaraMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Drissa CoulibalyMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Kirsten E LykeMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Matthew B LaurensMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-3874-581X
Matthew AdamsMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Shannon Takala-HarrisonMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jozelyn PabloDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, Irvine, California, USA.
Algis JasinskasDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, Irvine, California, USA.
Rie NakajimaDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, Irvine, California, USA.
Amadou NiangalyMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Bourema KouribaMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Abdoulaye K KoneMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
J Alexandra RoweCentre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Ogobara K DoumboMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Mahamadou A TheraMalaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali.
Jigar J PatelRoche NimbleGen, Inc., Madison, Wisconsin, USA.
John C TanRoche NimbleGen, Inc., Madison, Wisconsin, USA.
Philip L FelgnerDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, Irvine, California, USA.
Christopher V PloweDuke Global Health Institute, Duke University, Durham, North Carolina, USA.
Mark A TravassosMalaria Research Program, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA mtravass@som.umaryland.edu.ORCID 0000-0002-6045-3322
University of Maryland, Baltimore · USUniversité des Sciences, des Techniques et des Technologies de Bamako · MLUniversity of California, Irvine · USLa Roche College · USCentre for Immunity, Infection and Evolution · GBDuke University · USEmmes (United States) · US
Funding
EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9MSafety, Immunogenicity and Efficacy of VaccineU19AI065683 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2005 to 2009
$4.7MMALARIA RESEARCH TRAINING IN MALID43TW001589 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2000 to 2015
$2.8MMalaria:Clinical Research and Trial Preparation Sites-26685346N01AI085346 · NIAID · Univ Maryland · 1998 to 2004
$2.8MImmuno-epidemiological epitope mapping of a blood stage malaria vaccine antigenR01AI093635 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2012 to 2015
$2.3MVariant surface antigens in cerebral malaria pathogenesisR01HL130750 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI FISHER, STEVEN A., PLOWE, CHRISTOPHER V. · 2015 to 2018
$2.1MProtein microarray antibody responses to P. falciparum in a human challenge modelK23AI125720 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2017 to 2021
$915kHost vulnerability and parasite genetics in the development of cerebral malariaR01AI099628 · NIAID · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI THERA, MAHAMADOU ALI · 2014 to 2018
$625kUltra-dense peptide array analysis of naturally acquired and vaccine-induced P. falciparum immunityR21AI119733 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2016 to 2017
$361kFIC NIH HHS D43 TW001589Howard Hughes Medical InstituteNHLBI NIH HHS R01 HL130750NIAID NIH HHS K23 AI125720NIAID NIH HHS N01 AI085346NIAID NIH HHS R01 AI093635NIAID NIH HHS R01 AI099628NIAID NIH HHS R21 AI119733NIAID NIH HHS U19 AI065683NIGMS NIH HHS R25 GM055036
Abstract
The repetitive interspersed family (RIFIN) and the subtelomeric variable open reading frame (STEVOR) family represent two of three major
Indexed as
AdolescentAdultAge FactorsAntibodies, ProtozoanAntigens, ProtozoanChildChild, PreschoolClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicEndemic DiseasesFemaleHumansImmunity, InnateInfantInterspersed Repetitive SequencesMalariaAntibodies, ProtozoanAntigens, ProtozoanPeptidesSTEVOR antigen, Plasmodium falciparummalariamicroarrayspeptidePlasmodium falciparumRIFINsemiconserved domainsevere malariaSTEVORvariant surface antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.